CoChat

Patient perspectives of lithium and quetiapine augmentation treatment in treatment‐resistant depression: a qualitative assessment

Open access
McKeown, Lucas, Taylor, Rachael W, Day, Elana, Shah, Rupal, Marwood, Lindsey, Tee, Helena, Kerr-Gaffney, Jess, Oprea, Emanuella, Geddes, John R, McAllister-Williams, R Hamish, Young, Allan H, Cleare, Anthony J · 2022 · Journal of Psychopharmacology

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

Background: Treatment-resistant depression (TRD) has a profound cost to patients and healthcare services worldwide. Pharmacological augmentation is one therapeutic option for TRD, with lithium and quetiapine currently recommended as first-line agents. Patient opinions about pharmacological augmentation may affect treatment outcomes, yet these have not been systematically explored. Aims: This study aimed to qualitatively assess patient experiences of lithium and quetiapine augmentation. Methods: Semi-structured interviews were conducted with 32 patients from the ongoing lithium versus quetiapine open-label trial comparing these augmentation agents in patients with TRD. Interviews were audio recorded, transcribed and a thematic analysis was used to assess patient opinions of each agent. Results: Four main themes were generated from the thematic analysis: ‘Initial concerns’, ‘Experience of side effects’, ‘Perception of treatment efficacy’ and ‘Positive perception of treatment monitoring’. Patient accounts indicated a predominantly positive experience of lithium and quetiapine augmentation. Greater apprehension about side effects was reported for lithium prior to treatment initiation, but greater experience of negative side effects was reported for quetiapine. Clinical monitoring was perceived positively. Conclusion: Patient accounts suggested treatment augmentation with lithium or quetiapine was acceptable and helpful for most patients. However, anticipation and experiences of adverse side effects may prevent some patients from benefitting from these treatments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/02698811221089042

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Research works printed but not linked: 1

  1. QSR International Ltd, 2012, NVivo 10

Cited by

See all 12

Metadata

Authors
McKeown, L., Taylor, R. W., Day, E., Shah, R., Marwood, L., Tee, H., Kerr-Gaffney, J., Oprea, E., Geddes, J. R., McAllister-Williams, R. H., Young, A. H., & Cleare, A. J.
Affiliations
  • King's College London (GB)
  • Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
  • Oxford Health NHS Foundation Trust (GB)
  • Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK
Venue
Journal of Psychopharmacology
Published
2022-04-27
Volume
36
Issue
5
Pages
557-565
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W4225005363
Cited by
12
References
39
Citations by year
2026: 1 · 2025: 4 · 2024: 4 · 2023: 1 · 2022: 2
FWCI
1.65
Type
journal article
Language
en
Open access
Locations
  • Journal of Psychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by)
Funders
Health Technology Assessment Programme (14/222/02)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
treatment-resistant depression, drug augmentation, lithium, quetiapine, patient experience, adverse effects, treatment monitoring, treatment acceptability
MeSH terms
Quetiapine Fumarate, Antidepressive Agents, Depression, Drug Therapy, Combination, Humans, Lithium, Antipsychotic Agents, Treatment Outcome, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patient perspectives of lithium and quetiapine augmentation treatment in treatment‐resistant depression: a qualitative assessment. https://app.cochat.ai/papers/10.1177/02698811221089042
The paper
McKeown, L., Taylor, R. W., Day, E., Shah, R., Marwood, L., Tee, H., Kerr-Gaffney, J., Oprea, E., Geddes, J. R., McAllister-Williams, R. H., Young, A. H., & Cleare, A. J. (2022). Patient perspectives of lithium and quetiapine augmentation treatment in treatment‐resistant depression: a qualitative assessment. Journal of Psychopharmacology. https://doi.org/10.1177/02698811221089042

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.